Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07071480

Noninvasive Therapy for Tinnitus

The goal of this interventional clinical study is to establish mild therapeutic hypothermia, delivered non-invasively to the structures of the inner ear, as a safe and repeatable therapeutic method for symptomatic relief of tinnitus. The study will assess both objective and subjective measures to address two main aims:

1. Ascertain the benefits of mild therapeutic hypothermia for symptomatic relief of chronic tinnitus in participants using the ReBound hypothermia device. 2. Ascertain the benefits of mild therapeutic hypothermia for symptom management in chronic tinnitus participants over six months using the ReBound device.

Participants will wear the ReBound hypothermia device for 30 minutes in a single session. Researchers will compare results from those receiving the therapy to those from a control group (sham therapy). Participants will also use the device in-home for 6 months and monitor their symptoms with online surveys.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Miami

Miami, Florida, 33136, United States

Location status: Recruiting

Location contact

Hillary Snapp, AuD

SUB_INVESTIGATOR

Suhrud M Rajguru, PhD

CONTACT

[email protected]

801-641-8180

Suhrud M Rajguru, PhD

PRINCIPAL_INVESTIGATOR

About this study

Tinnitus is the perception of sound in the absence of an external stimulus commonly described as ringing in the ears. Tinnitus is a highly common condition, with most individuals experiencing it at some point in their lifetime. At least 1 in 10 US adults experience chronic or disabling tinnitus [1] with a significant negative impact on quality of life, often affecting sleep, concentration, mood, and hearing ability. Tinnitus can be intermittent or constant in nature, and intensity can vary or be exacerbated by stress, noise exposure, or other factors. Currently, there is no widely applicable cure for tinnitus, and management typically includes use of sound therapy, mental health counseling, lifestyle modifications, stress management, and distraction techniques, all of which serve to mask symptoms without addressing underlying physiology. Tinnitus is associated with changes in auditory function, with hearing loss being the most associated co-morbidity in patients. However, tinnitus can also be observed in patients with audiometrically normal hearing [2, 3].

Tinnitus can have a significant deleterious effect on a person's quality of life, and there is currently no cure. State-of-the art treatment options suffer limitations and are often ineffective and complex. Most widely used tinnitus treatments focus on reducing awareness of tinnitus/masking symptoms and the impact on emotional state rather than seeking to address the underlying mechanisms of the sound generation [4]. Treatment modalities include sound therapy using environmental sounds and/or hearing aids, psychological interventions including tinnitus retraining therapy and/or cognitive behavioral therapy, somatosensory stimulation including vagus nerve stimulation and osteopathic manipulation, and distraction exercises including guided breathing and development of new hobbies. Other therapies aim to target the generation of tinnitus, including direct and indirect stimulation of the auditory cortex and/or other brain structures through neuromodulation and pharmacologics [5]. Despite the limited success of many of these treatment modalities, none have been shown to be widely applicable to manage tinnitus severity or provide a treatment for tinnitus. Further, systematic reviews have failed to demonstrate a strong evidence base for these approaches [1]. Many treatments and strategies currently in research are costly in terms of both time and resources, reducing sufferers' access or their ability to continue treatment over time. For those who do not find relief from their debilitating symptoms, and for those seeking to address secondary effects of tinnitus, there exists a need for novel treatment aimed at reducing acute tinnitus severity [6].

The investigators propose to show the efficacy of a highly accessible and translatable, non-invasive device utilizing mild therapeutic hypothermia, or MTH, to reduce tinnitus severity in participants with tinnitus. Unlike other approaches, MTH will address the physiological mechanisms of tinnitus and is easily deployable for routine use and symptom management. With support from a prior SBIR Phase I award, the investigators have designed and manufactured the headband-style device, ReBoundTM, to provide therapeutic hypothermia to the inner ear structures. Modifying temperature of the cochlea is known to influence auditory responses [7-12]. The investigators and others have shown that MTH delivered locally or systemically protects hearing function and cochlear structures against noise-induced hearing loss when compared to normothermic animals [13]. The present study builds upon strong preliminary and published results of MTH treatment in the inner ear [14, 15] and two additional new publications [16, 17].

The goal of this interventional clinical study is to establish mild therapeutic hypothermia, delivered non-invasively to the structures of the inner ear, as a safe and repeatable therapeutic method for symptomatic relief of tinnitus. The study will assess both objective and subjective measures to address two main aims:

  • Ascertain the benefits of mild therapeutic hypothermia for symptomatic relief of chronic tinnitus in participants using the ReBound hypothermia device.
  • Ascertain the benefits of mild therapeutic hypothermia for symptom management in chronic tinnitus participants over six months using the ReBound device.

Participants will wear the ReBound hypothermia device for 30 minutes in a single session. Researchers will compare results from those receiving the therapy to those from a control group (sham therapy). Participants will also use the device in-home for 6 months and monitor their symptoms with online surveys.

This research will be highly impactful given the significant adverse effects of tinnitus, an unmet clinical need, on a broad population, and the high translational potential of MTH for reducing tinnitus symptoms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 years or older at the time of signing the consent form
  • Fluency in English or Spanish
  • Chronic subjective tinnitus for more than 30 days defined as audible at least 75% of waking hours
  • At least mild tinnitus, score ≥18 on the Tinnitus Handicap Inventory (THI)

Exclusion criteria

  • Severe anxiety, score ≥ 15 on the Generalized Anxiety Disorder-7 (GAD-7)
  • Tinnitus described as non-auditory or pulsatile in nature
  • Catastrophic tinnitus, score ≥78 on the THI
  • Tinnitus that is intermittent in nature
  • Abnormal tympanometric findings
  • Presence of conductive component as characterized by air-bone gaps ≥15 dB at two or more consecutive frequencies
  • Otologic pathologies (including, but not limited to): acoustic neuroma/ vestibular schwannoma, chronic ear disease, Meniere's disease, documented fluctuating hearing loss, or ototoxicity
  • Temporomandibular joint disorder
  • Those who are currently receiving medical, pharmacologic, or therapeutic intervention for tinnitus or other otologic conditions.
  • Active hearing aid use
  • Dizziness at the time of signing the consent form or at the time of starting the study protocol treatment
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners

Treatment and study plan

Cold pack-delivered mild therapeutic hypothermia

Device

Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBound.

Sham device

Device

Sham headband-style device. Participants assigned to use this device will be told they are receiving therapy for 30 minutes. However, no therapy is being provided.

Primary outcomes

  1. Visual Analog Scale (VAS) of Tinnitus Severity

    Time frame: VAS will be given to participants in both Experimental and Sham Arms. For Aim 1, VAS will be administered at baseline, immediately after treatment, and at 24 hours post-treatment. For Aim 2, VAS will be administered monthly for 6 months post-baseline.

    3-item instrument used to assess participant's subjective perception of tinnitus. Includes sliding scales used by participants to score their perceived disease severity. VAS will be used to assess perceived tinnitus severity before baseline treatment and repeated immediately after treatment. The VAS consists of a sliding scale from 0 to 10, with 10 correlating to a greater disease burden/worse symptoms.

  2. Tinnitus Functional Index Adapted (TFI-Adapted)

    Time frame: TFI-Adapted will be given to participants in Aim 1. TFI-Adapted will be administered at baseline and 24 hours post-treatment.

    25-item instrument with eight subscales; (1) Intrusiveness, (2) Sense of control, (3) Cognition, (4) Sleep, (5) Auditory, (6) Relaxation, (7) Quality of life, and (8) Emotional distress. Each subscale can be scored separately, allowing for relevant items to be summed and weighted for analysis. TFI questions will be adapted to ask participants about their tinnitus experience over the past 24 hours.

Secondary outcomes

  1. Pure Tone Audiometry

    Time frame: PTA will be measured in Aim 1 at baseline and immediately after treatment.

    PTA will be measured in Aim 1 for frequencies 250 - 8,000 Hz and high frequencies of > 8,000 Hz.

  2. Distortion Product Otoacoustic Emissions (DPOAE)

    Time frame: DPOAE will be measured in Aim 1 at baseline and immediately after treatment.

    DPOAE will be measured in Aim 1 for 1,500 - 10,000 Hz. DPOAEs will be recorded and analyzed using f2 tone frequencies with a fixed primary ratio (f2/f1) of 1.22, L1 = 65 dB SPL, L2 = 55 dB SPL.

  3. Auditory Brainstem Response (ABR)

    Time frame: ABR will be measured in Aim 1 at baseline and immediately after treatment.

    Test measuring the brain's electrical activity in response to sound to assess hearing and neurological function. ABR will be recorded using 77 dB nHL. At least 2 averaged responses will be performed to ensure replicability.

  4. Tinnitus Pitch & Loudness Matching

    Time frame: Tinnitus pitch and loudness matching will be measured in Aim 1 at baseline and immediately after treatment.

    Psychoacoustic measurements of each participant's tinnitus will be performed to qualify tinnitus pitch.

  5. Tinnitus Functional Index (TFI)

    Time frame: TFI will be given to participants in Aim 2. TFI will be administered monthly for 6 months post-baseline.

    25-item instrument with eight subscales; (1) Intrusiveness, (2) Sense of control, (3) Cognition, (4) Sleep, (5) Auditory, (6) Relaxation, (7) Quality of life, and (8) Emotional distress. Each subscale can be scored separately, allowing for relevant items to be summed and weighted for analysis.

Other outcomes

  1. Tinnitus Handicap Inventory (THI)

    Time frame: The THI will be administered as part of enrollment determination and at 6 months post-baseline.

    25-item instrument used to assess the handicap experienced by the participant due to tinnitus. THI assesses functional, emotional, and catastrophic response reactions to tinnitus on a 4-point scale totaling 100, with degree of handicap increasing with score.

  2. Tinnitus Therapy Use

    Time frame: This instrument will be administered monthly for 6 months post-baseline.

    2-question survey to collect data on the number of times the ReBound device was worn in the past month.

  3. Adverse Event Questionnaire (AEQ)

    Time frame: AEQ will be administered immediately after treatment, 24 hours post-treatment, and monthly for 6 months post-baseline.

    2-question survey to collect data on any adverse event associated with use of the device.

Study contacts

Contact information is provided by the study sponsor or research team.

Kristine Harris

CONTACT

[email protected]

305-243-4611

Suhrud M Rajguru, PhD

CONTACT

[email protected]

801-641-8180

Sponsors and collaborators

Lead sponsor

Restorear Devices LLC

Industry

Collaborators

  • National Institute on Deafness and Other Communication Disorders (NIDCD)
  • University of Miami

Registry information

Official study title

Noninvasive Therapeutic Hypothermia for Tinnitus

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jul 17, 2025
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.